Microparticles as a Biomarker of Incident Cardiovascular Risk in Patients With Obstructive Sleep Apnea
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- myocardial infarction (acute infarct or silent myocardial infarction or unstable angina)
研究概览
简要总结
Obstructive sleep apnea (OSA) is independently associated with cardiovascular diseases, including myocardial infarction and stroke. OSA may promote atherosclerosis risk factors such as hypertension, diabetes and dyslipidemia and may have direct proatherogenic effects on the vascular wall. A growing number of studies have recently focused on the role of microparticles (MPs) in the atherogenic process. Case-control studies have shown that platelet-, endothelial- and leukocyte-derived MP levels are increased in OSA and that leukocyte-derived MP are released during the night in OSA. Furthermore, experimental evidence shows that MPs from OSA patients induce endothelial dysfunction.
The objective of this prospective study is to evaluate the impact of increased levels of leukocyte derived MPs on the cardiovascular outcomes in patients with prevalent cardiovascular diseases investigated for OSA.
详细描述
MPs are small plasma membrane vesicles that can be released by a variety of vascular or blood cells and that contain membrane and cytosolic elements. Case-control studies have shown that platelet-, endothelial- and leukocyte-derived MP levels are increased in OSA. Experimental evidence shows that MPs from OSA patients induce endothelial dysfunction, inflammation, and vascular hyperreactivity when injected to mice.
The impact of increased levels of MPs on the cardiovascular prognosis in OSA patient with prevalent cardiovascular diseases in unknown.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of coronary artery disease or cerebrovascular disease
- •diagnosis of moderate-to-severe OSA
排除标准
- •pregnancy
- •previously treated OSA
结局指标
主要结局
myocardial infarction (acute infarct or silent myocardial infarction or unstable angina)
时间窗: first event within 5 years after inclusion
outcomes assessed every year at the follow up visit or by calling the primary care physician
cerebrovascular infarction (stroke or transient ischemic attack)
时间窗: first event within 5 years after inclusion
outcomes assessed every year at the follow up visit or by calling the primary care physician
death from any cardiovascular cause
时间窗: first event within 5 years after inclusion
outcomes assessed every year at the follow up visit or by calling the primary care physician
hospitalization for heart failure
时间窗: first event within 5 years after inclusion
outcomes assessed every year at the follow up visit or by calling the primary care physician
次要结局
未报告次要终点